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Originating	Technology/NASA	Contribution
Ever	 stand	 up	 too	 quickly	 from	 a	 sitting	 or	lying	 position	 and	 feel	 dizzy	 or	 disoriented	for	 a	 brief	moment?	The	 downward	 push	 of	
Earth’s	gravity	naturally	causes	blood	to	settle	in	the	
lower	 areas	 of	 the	 human	 body,	 and	 occasionally,	
with	a	quick	movement—such	as	rising	swiftly	from	
a	chair—the	body	is	not	able	to	adjust	fast	enough	to	
deliver	an	adequate	supply	of	blood	to	the	upper	parts	
of	 the	body	and	 the	brain.	This	 sudden,	 temporary	
drop	in	blood	pressure	is	what	causes	brief	feelings	of	
lightheadedness	upon	standing.	In	essence,	when	the	
heart	pumps	blood	to	different	parts	of	the	body,	it	is	
working	against	the	physical	phenomenon	of	gravity	in	
its	efforts	to	send	blood	up	to	the	brain.	
In	more	cases	than	not,	the	body	is	able	to	make	the	
necessary	adjustments	to	ensure	proper	blood	flow	and	
pressure	to	the	brain;	but	when	the	disorientation	lasts	a	
long	time	and/or	become	chronic,	individuals	may	have	a	
condition	called	orthostatic	intolerance.	According	to	the	
American	Journal	of	Physiology–Heart	and	Circulatory	
Physiology,	an	estimated	500,000	Americans	are	affected	
by	orthostatic	intolerance.	Symptoms	range	from	occa-
sional	 fainting,	blurry	 vision,	 and	pain	or	discomfort	
in	 the	head	and	the	neck,	 to	 tiredness,	weakness,	and	
a	lack	of	concentration.	Though	research	indicates	that	
the	 condition	 is	 not	 life-threatening,	 it	 could	 impact	
the	quality	of	life	and	contribute	to	falls	that	result	in	seri-
ous	injuries.
The	 condition	 is	 a	 prominent	 concern	 for	NASA,	
since	 astronauts	 have	 to	 readjust	 to	 the	 gravitational	
environment	 of	 Earth	 after	 spending	 days	 in	 the	
weightlessness	 of	 space.	NASA’s	Exploration	Systems	
Mission	Directorate	has	found	that	roughly	20	percent	
of	astronauts	coming	off	of	short-duration	space	flights	
experience	difficulty	maintaining	proper	blood	pressure	
when	moving	from	lying	down	to	either	sitting	or	standing	
during	the	first	few	days	back	on	Earth.	The	difficulties	
are	even	more	severe	for	astronauts	coming	off	of	long-
duration	missions,	according	to	the	mission	directorate,	as	
83	percent	of	these	crewmembers	experience	some	degree	
of	the	condition.	
Cardiovascular	 experts	 at	 NASA	 have	 found	 that	
the	 blood	 that	 normally	 settles	 in	 the	 lower	 regions	
of	the	body	is	instead	pulled	to	the	upper	body	in	the	
microgravity	 environment	 of	 space.	 Blood	 volume	 is	
subsequently	 reduced	 as	 some	 cardiovascular	 reflexes	
are	no	 longer	being	used,	 and	 less	blood	 flows	 to	 the	
legs.	Additionally,	the	muscles	weaken,	especially	in	the	
lower	portion	of	the	body,	because	they	are	not	working	
(contracting)	as	hard	as	they	usually	do.	This	is	not	so	
much	 a	 concern	 for	 the	 astronauts	while	 they	 are	 in	
space,	since	the	action	of	floating	around	takes	the	place	
of	putting	center-of-gravity	pressure	on	their	legs.	(They	
do	exercise	strenuously	while	in	microgravity,	though,	to	
keep	their	muscles	and	circulatory	systems	conditioned,	
thus	preparing	their	bodies	for	the	return	to	gravity	as	
best	 they	 can.)	When	 they	 return	 to	 Earth’s	 gravity,	
however,	more	blood	returns	to	the	legs.	Since	there	is	
a	lower	volume	of	blood,	the	flow	that	is	supposed	to	be	
traveling	to	the	brain	can	be	insufficient.	That	is	when	
orthostatic	intolerance	can	set	in.	
NASA	 has	 conducted	 and	 sponsored	 a	 wealth	 of	
studies	to	counter	the	effects	of	orthostatic	intolerance,	
especially	since	the	condition	could	prevent	an	astronaut	
from	 exiting	 a	 landed	 spacecraft	 in	 the	 event	 of	 an	
emergency.	In	one	study	conducted	by	Johnson	Space	
Center’s	Cardiovascular	Laboratory,	astronauts	in	orbit	
tested	the	efficacy	of	a	drug	called	midodrine	that	has	
successfully	reduced	orthostatic	intolerance	in	patients	
on	Earth.	The	early	results	were	promising,	but	further	
testing	will	be	conducted	by	the	laboratory	before	more	
conclusive	results	can	be	determined.	In	another	study,	
the	laboratory	is	using	a	controlled	tilt	test	on	Earth	to	
replicate	the	body’s	responses	to	a	shift	from	reclining	to	
sitting	or	standing.	
At	Ames	Research	Center,	 researchers	 are	utilizing	
NASA’s	20-G	artificial	gravity	centrifuge	machine	in	a	
pilot	study	on	cardiovascular	responses	and	fluid	shifts	
in	 the	body.	A	 separate	Ames	 study	 is	 evaluating	 the	
possibility	 of	 expanding	 astronauts’	 plasma	 volumes	
(the	fluid	part	of	the	blood,	minus	the	blood	cells),	as	a	
preventative	measure.	
Circulation-Enhancing Device Improves CPR
The ResQPOD is an impedance threshold device used to 
enhance circulation during CPR. It could be used to increase 
circulation for astronauts as their bodies initially adjust to a 
return to gravity from the weightlessness of space.
https://ntrs.nasa.gov/search.jsp?R=20080003935 2019-08-30T02:07:06+00:00Z
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In	NASA-sponsored	research	at	Vanderbilt	University,	
researchers	have	successfully	identified	a	genetic	cause	for	
orthostatic	 intolerance.	The	 findings	marked	 the	 first	
time	a	genetic	defect	had	been	linked	to	a	disorder	of	the	
autonomic	immune	system,	according	to	the	discoverers,	
and	could	eventually	lead	to	new	drugs	and	treatments	for	
the	condition.
At	Kennedy	Space	Center,	 a	 collaborative	 research	
effort	with	the	U.S.	Army	and	private	industry	has	yielded	
an	important	application	for	a	new,	non-invasive	medical	
device	called	ResQPOD	that	is	now	available	for	astro-
nauts	returning	from	space.	In	helping	to	reacquaint	the	
astronauts	with	the	feeling	of	gravity,	ResQPOD	quickly	
and	effectively	increases	the	circulation	of	blood	flow	to	
the	brain.	This	device	is	also	available	to	the	public	as	a	
means	to	enhance	circulation	for	breathing	patients	suf-
fering	from	orthostatic	intolerance	and	for	non-breathing	
patients	suffering	cardiac	arrest	or	other	high-risk	clinical	
conditions	attributed	to	low	blood	pressure.	
Partnership
Advanced	Circulatory	Systems	Inc.,	of	Minneapolis,	
collaborated	with	Kennedy	and	the	U.S.	Army	Institute	
of	Surgical	Research	for	more	than	5	years	to	develop	
ResQPOD.	Don	Doerr,	an	engineer	at	Kennedy,	led	the	
testing	and	development	effort;	Dr.	Victor	Convertino	of	
the	Institute	of	Surgical	Research	(and	a	former	NASA	
scientist	at	Kennedy)	also	played	an	instrumental	role	in	
developing	the	technology.	
Multiple	clinical	studies	were	conducted	during	the	
research	 effort,	 including	 six	 published	 studies.	 The	
published	works	demonstrate	 that	ResQPOD	offers	a	
significant	 improvement	 in	 cardiac	output	 and	blood	
flow	to	the	brain	and	in	preventing	shock	in	the	event	
of	considerable	blood	loss,	when	compared	to	conven-
tional	resuscitation.	According	to	Advanced	Circulatory	
Systems,	data	 from	the	NASA	studies	played	a	major	
role	 in	 the	 company	 obtaining	U.S.	 Food	 and	Drug	
Administration	501K	clearance	for	the	device.
The ResQPOD increases circulation in states of low blood pressure. When used on patients in cardiac arrest, the ResQPOD 
harnesses the chest wall recoil after each compression to generate a small but critical vacuum within the chest. This vacuum 
enhances blood flow back to the heart and results in a marked increase in blood flow out of the heart with each subsequent 
chest compression.
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The ResQPOD 
doubles blood flow 
back to the heart. 
CPR delivers 
approximately 1 
percent of normal blood 
flow to the heart.
During the decompression (release) phase of 
CPR, an increase in negative pressure in the 
thoracic cavity results in drawing more blood 
back into the chest, providing greater venous 
return to the heart.
Dr.	Keith	Lurie,	chief	medical	officer	at	Advanced	
Circulatory	Systems	and	a	primary	member	of	the	collab-
orative	research	effort,	said,	“The	three-way	partnership	
between	NASA,	private	 industry,	 and	 the	U.S.	Army	
Institute	of	Surgical	Research	is	really	a	model	for	how	
organizations	can	work	together	to	benefit	both	govern-
ment	programs	and	civilians.”
In	2006,	Dr.	Smith	Johnston,	the	lead	flight	surgeon	
for	NASA’s	 space	 shuttle	missions,	 added	ResQPOD	
to	 the	 list	 of	medical	 equipment	 that	 is	 available	 for	
returning	astronaut	crews.	The	device	was	on	hand	for	
the	 landing	 of	 Space	 Shuttle	 Atlantis	 (STS-115)	 on	
September	21,	2006.	
“We’re	 excited	 that	 our	 devices	were	 available	 to	
the	medical	team	[for	the	STS-115	mission]	and	look	
forward	to	continued	collaboration	with	NASA	to	assist	
its	 efforts	 to	 safeguard	 the	health	of	 the	 astronauts,”	
added	Lurie.		 	
Product	Outcome
Manufactured	commercially	by	Advanced	Circulatory	
Systems	 and	 distributed	 by	 Sylmar,	California-based	
Tri-anim	Health	Services	Inc.,	the	ResQPOD	circulatory	
enhancer	improves	upon	the	standard	of	care	for	patients	
with	a	variety	of	clinical	conditions	associated	with	low	
blood	 flow.	 Advanced	 Circulatory	 Systems’	 primary	
commercial	focus,	though,	is	on	non-breathing	patients	
who	can	benefit	from	enhanced	circulation,	such	as	those	
experiencing	cardiac	arrest.	
According	to	the	American	Heart	Association,	about	
900	Americans	fall	victim	to	sudden	cardiac	arrest	every	
day,	with	approximately	95	percent	dying	before	they	
reach	the	hospital.	This	is	why	cardiopulmonary	resus-
citation	(CPR)	can	mean	the	difference	between	life	and	
death,	as	 increasing	blood	flow	to	the	heart	and	brain	
until	the	heart	can	be	restarted	is	critical	to	improving	
survival	rates	with	normal	neurological	functioning.	
ResQPOD	is	an	American	Heart	Association-rated	
Class	IIa	impedance	threshold	device,	meaning	that	it	is	
the	highest	recommended	“adjunct”	in	the	association’s	
latest	 guidelines	 for	 CPR.	 As	 a	 Class	 IIa	 impedance	
threshold	device,	it	also	carries	a	higher	recommendation	
than	any	medication	used	to	boost	circulation	in	adults	
suffering	cardiac	arrest,	according	to	these	guidelines.	
The	device	is	about	the	size	of	a	fist	and	can	be	affixed	
to	either	a	facemask	or	an	endotracheal	breathing	tube	
during	CPR.	It	enhances	the	intrathoracic	vacuum	that	
forms	in	the	chest	during	the	chest	recoil	phase	of	CPR	
by	 temporarily	 sealing	off	 the	airway	between	breaths	
and	preventing	unnecessary	air	from	entering	the	chest	
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as	 50	percent.	At	Cypress	Creek	Emergency	Medical	
Services	(EMS),	a	large	medical	care	organization	serv-
ing	more	than	400,000	residents	in	the	greater	Houston	
area,	ResQPOD	has	become	a	standard	of	care.	Overall	
resuscitation	 rates	 climbed	 to	nearly	50	percent	 since	
the	organization	began	deploying	 the	device	 in	2005,	
boosting	hospital	admission	rates	from	26	percent	to	an	
astounding	38	percent.	
“These	results	are	gratifying,	and	we	applaud	the	entire	
Cypress	Creek	 EMS	 organization	 for	 their	 advanced	
emergency	medical	service	care	and	their	ability	to	turn	
around	the	dismal	statistics	that	surround	cardiac	arrest,”	
noted	Advanced	Circulatory	Systems’	Lurie.
In	its	secondary	commercial	applications,	Advanced	
Circulatory	Systems	is	offering	ResQPOD	to	improve	cir-
culation	in	patients	suffering	from	orthostatic	intolerance	
and	general	low	blood	pressure.	These	secondary	uses	also	
(timing-assist	 lights	on	 the	device	will	aid	 the	 rescuer	
in	ventilating	the	patient	at	a	proper	rate).	The	vacuum	
that	is	created	pulls	blood	back	to	the	heart,	doubling	
the	amount	of	blood	that	is	pulled	back	by	conventional	
mouth-to-mouth/chest	compression	CPR,	according	to	
clinical	studies,	which	also	show	that	blood	flow	to	the	
brain	 is	 increased	by	50	percent.	 In	sustaining	proper	
blood	 flow	 to	 the	heart	 and	 to	 the	brain,	ResQPOD	
increases	the	likelihood	of	survival	and	decreases	the	like-
lihood	of	neurological	disorders.
ResQPOD	is	being	used	by	emergency	medical	tech-
nicians	in	cities	all	around	the	country,	including	Boston,	
Houston,	Indianapolis,	Miami,	and	Oklahoma	City,	as	
well	as	Hartford,	Connecticut;	Kansas	City,	Missouri;	
Raleigh,	North	Carolina;	and	Toledo,	Ohio.	 In	 some	
cities,	it	has	reportedly	increased	the	number	of	cardiac	
arrest	patients	delivered	alive	to	the	hospital	by	as	much	
apply	to	individuals	who	undergo	dialysis	treatments	and	
may	experience	a	drop	in	blood	pressure,	as	well	as	those	
who	go	into	shock	after	severe	blood	loss.
Outside	of	the	traditional	hospital	setting,	the	com-
pany	 is	 investigating	the	beneficial	 impact	ResQPOD	
could	have	on	wounded	soldiers	in	the	battlefield	who	
may	have	lost	a	great	deal	of	blood	and	are	in	danger	of	
going	into	shock.	
Advanced	Circulatory	Systems	is	also	harnessing	the	
physiological	principles	discovered	during	 its	 research	
collaboration	with	NASA	to	develop	another	promis-
ing	technology:	an	intrathoracic	pressure	regulator	for	
patients	requiring	ventilation	assistance	because	they	are	
too	sick	to	breathe	on	their	own.	v
ResQPOD®	is	a	registered	trademark	of	Advanced	Circulatory	
Systems	Inc.		
CPR delivers 
approximately  
percent of normal 
blood flow to the brain.
The ResQPOD delivers 
more than 0 percent 
of normal blood flow to 
the brain.
Improved venous return results in increased 
cardiac output during the subsequent 
compression phase of CPR, providing greater 
blood flow to the brain.
